Who Generates Higher Gross Profit? Biogen Inc. or Travere Therapeutics, Inc.

Biogen Inc. vs. Travere Therapeutics, Inc.: A Decade of Gross Profit Analysis

In the competitive landscape of biotechnology, understanding which companies lead in profitability is crucial. Over the past decade, Biogen Inc. has consistently outperformed Travere Therapeutics, Inc. in terms of gross profit. From 2014 to 2023, Biogen's gross profit peaked in 2019, reaching approximately $12.4 billion, while Travere's highest was around $220 million in 2021. This stark contrast highlights Biogen's dominance, with its profits being nearly 50 times greater than Travere's at their respective peaks.

Biogen's gross profit saw a decline post-2019, dropping to about $7.3 billion by 2023, a 41% decrease. Meanwhile, Travere's profits showed a more stable trend, with a modest increase of 384% from 2014 to 2021. This data underscores the varying scales and growth trajectories of these two companies, offering valuable insights for investors and industry analysts alike.